CatalystHCConsulting

Catalyst Healthcare Consulting, Inc.: a strategic policy &reg. affairs advisory firm helping cutting-edge companies chart the best paths fwd. #HHS #FDA experts.

[CatalystHCConsulting @Catalyst_HC_C]

Watch Catalyst and other experts in this @Pharma_Intell webinar share tips and best practices for engaging #FDA in virtual meetings during #COVID19 and possibly beyond: https://t.co/SUpcwDiXuy

[CatalystHCConsulting @Catalyst_HC_C]

Catalyst's Jeff Myers discusses what the future holds for #Medicaid and how #COVID19 will impact the public payor space in the near term at the @MostlyMedicaid 2020 Summer Virtual Conference:
https://t.co/wJm9VRqQSu

[CatalystHCConsulting @Catalyst_HC_C]

Want to hear tips and approached for engaging FDA in virtual meetings? Come hear Nancy Myers @FDAinsightguru at @Pharma_Intell's free COVID-19 24-hr Web Event on Tues 7/21 3pm ET on the panel: How to Work With the US FDA When You Can’t Meet With Them
https://t.co/IngmyAtfwk

[CatalystHCConsulting @Catalyst_HC_C]

In today's @PharmaPinkSheet, Catalyst's Nancy Myers
@FDAinsightguru commends how #FDA “Marks and Woodcock recognize they can’t be both referee and player” as they recuse themselves from reviewing #COVID19 products while working on #OperationWarpSpeed. https://t.co/nfHru7Vg6G

[CatalystHCConsulting @Catalyst_HC_C]

In @AISHealth, Catalyst’s Jeff Myers weighs in on the #SCOTUS 8-1 ruling of #CMS owing billions to health insurers in risk corridor funding, discussing while it’s mandated by law, the risk corridor program isn’t well designed to begin with. https://t.co/gUVGtL4CzJ

[CatalystHCConsulting @Catalyst_HC_C]

In @thehill, Catalyst’s Jeff Myers argues it’s unlikely early #COVID19 treatments will have remarkably high efficacy, but it’s still worth making and having them be available options to combat the deadly #coronavirus. https://t.co/O7NOpZjSDy

[CatalystHCConsulting @Catalyst_HC_C]

Catalyst’s Jeff Myers discusses how the #COVID19 outbreak is affecting #Medicaid enrollment and how this can influence health insurers’ financial considerations and states’ budgets (original post from
@AISHealth) - https://t.co/KY4RJlOXeE

[CatalystHCConsulting @Catalyst_HC_C]

Jeff Myers, SVP Market Access & Reimbursement Strategies at Catalyst, weighs in on CMS #Medicaid waivers as an effort to help states improve their #COVID19 responses (original post from @AISHealth) - https://t.co/wXLGUD0fus

[CatalystHCConsulting @Catalyst_HC_C]

Surf’s up! 😎☀️ Catalyst Healthcare Consulting's @FDAinsightguru weighs in on how the FDA is preparing to ride the gene and cell therapy wave 🌊 in a @PharmaPinkSheet op-ed: https://t.co/RFj36Y9eSk
#FDA #CBER #GeneTherapy

[CatalystHCConsulting @Catalyst_HC_C]

Congratulations to @realrickpazdur for winning the 2019 Dr. Harvey Wiley Lecture Award for his visionary leadership in oncology! Nancy Myers presented the award on behalf of the FDA Alumni Association. FDLI#annual19

[CatalystHCConsulting @Catalyst_HC_C]

Although digital medicines https://t.co/eQq6FZbhRg may not be the right solution for everyone, in some cases, it may be very important to patients' health to make sure they are taking their medicines as prescribed.

[CatalystHCConsulting @Catalyst_HC_C]

What was Gottlieb's special sauce as Commissioner? How will his departure impact FDA? Check out Nancy Myers' op-ed, on the silver lining of his exit. https://t.co/4YOQW9rpOf

[The Alliance for a Stronger FDA @StrengthenFDA]

@SGottliebFDA @POTUS Congrats to #FDA - we're excited the whole team will be back fulfilling FDA's critical mission. During the Shutdown, @SGottliebFDA focused on protecting public health, transparently communicated critical info, and provided empathy for impacted FDA employees. True leadership!

[CatalystHCConsulting @Catalyst_HC_C]

Way to go, @CancerResrch

[Nancy Bradish Myers @FDAinsightguru]

Another example of patients and advocates being fearless and being thought leaders! Go #FDA advocates supporting @SGottliebFDA; #FOCR #OpenFDA https://t.co/PKshzNNB6v

[CatalystHCConsulting @Catalyst_HC_C]

FDA shutdown - How might it affect innovation & public health? Why isn't anyone sounding alarm bells? Catalyst's Nancy Myers offers insights into how FDA is doing, and what she's most concerned about, in this guest column in Pharmaceutical Online. https://t.co/2PWfmfv9yq

[CatalystHCConsulting @Catalyst_HC_C]

How is @US_FDA doing under Gottlieb? Why does the agency seem to be accomplishing so much under this Commissioner? Check out Nancy Myers' op-ed in The Pink Sheet to understand FDA's special sauce recipe https://t.co/YAFuUUGJd5 .

[CatalystHCConsulting @Catalyst_HC_C]

FDA Office of the Commissioner reorg in the works; much of this is a return to the org chart under McClellan, along with 4 new Offices to be added. https://t.co/70eEsNc9S5

[FDA Drugs and Biologics @FDADrugs]

Patients with chronic pain and others can share their experiences & perspectives by submitting comments to the #ChronicPainPFDD public docket. To submit your comment, visit: https://t.co/AUHeNv7kqM and click “Comment Now”

[CatalystHCConsulting @Catalyst_HC_C]

#ICYMI FDA has issued a new draft guidance specifying labeling recommendations for drugs and biologics --> https://t.co/ElVfLaK3Uj

[CatalystHCConsulting @Catalyst_HC_C]

#RWE #clinicaltrials #FDA https://t.co/2BBfn5UKJN